Taxotere is an anti-cancer chemotherapy drug that also goes by the generic name Docetaxel. Taxotere is classified as a “plant alkaloid” and was approved by the FDA in 2006 for the cure of breast cancer, non-small cell lung cancer, radical stomach cancer, head and neck cancer and metastatic prostate cancer. The chemotherapy drug is also being studied to treat small cell lung cancer, ovarian cancer, bladder cancer and pancreatic cancer, soft tissue sarcoma and melanoma.
Taxotere is normally used in the blend with other drugs such as capecitabine, cisplatin, fluorouracil, doxorubicin and cyclophosphamide to contest off cancer and deliver patients with better existence rates. It acts as an anti-mitotic agent, sensing that it interrupts cellular division. It is usually managed intravenously during one hour-long infusion cycles that are then repeated every 3-4 weeks. Taxotere is a redundant chemo drug that is adding, even more, pain to women’s lives. One Taxotere drug consequence consists of permanent hair loss, called alopecia.
In addition to increasing the risk of permanent hair loss, Taxotere may source the following side effects in some users:
- Pain/swelling at the injection site
- Excessive tearing
Numerous Taxotere hair loss lawsuits have been filed against, the manufacturer, claiming the drug company being unsuccessful to warn of Taxotere hair loss. A woman filed a lawsuit against the makers of Taxotere. She claims the provocative breast cancer drug instigated her to develop permanent hair loss, a condition often stated to as everlasting alopecia.
Types of Alopecia:
- Alopecia Areata – Circular patches of hair loss
- Alopecia Totalis – Total hair loss on the scalp
- Alopecia Universalis – Total hair loss on the scalp and body
Attorneys state that if the maker had correctly warned of the risks, patients would have been recommended a different chemotherapy drug called Taxol, which is more operative than Taxotere, and does not result in stable hair loss. Taxotere and Taxol (generic: paclitaxel) are both categorised as taxanes. These medications display a high level of activity when used as single agents in metastatic breast cancer. In analyses of studies, when compared with standard therapies Taxotere seems to be the most dynamic single agent for treating metastatic breast cancer.